Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Hydrazone, benzohydrazones and isoniazid-acylhydrazones as potential antituberculosis agents.

Sampiron EG, Costacurta GF, Baldin VP, Almeida AL, Ieque AL, Santos NC, Alves-Olher VG, Vandresen F, Gimenes AC, Siqueira VL, Caleffi-Ferracioli KR, Cardoso RF, Scodro RB.

Future Microbiol. 2019 Jul;14:981-994. doi: 10.2217/fmb-2019-0040. Epub 2019 Aug 6.

PMID:
31382801
2.

Ginger essential oil and fractions against Mycobacterium spp.

Baldin VP, Bertin de Lima Scodro R, Mariano Fernandez CM, Ieque AL, Caleffi-Ferracioli KR, Dias Siqueira VL, de Almeida AL, Gonçalves JE, Garcia Cortez DA, Cardoso RF.

J Ethnopharmacol. 2019 Nov 15;244:112095. doi: 10.1016/j.jep.2019.112095. Epub 2019 Jul 17.

PMID:
31325601
3.

Eugenol and derivatives activity against Mycobacterium tuberculosis, nontuberculous mycobacteria and other bacteria.

de Almeida AL, Caleffi-Ferracioli KR, de L Scodro RB, Baldin VP, Montaholi DC, Spricigo LF, Nakamura-Vasconcelos SS, Hegeto LA, Sampiron EG, Costacurta GF, Dos S Yamazaki DA, F Gauze G, Siqueira VL, Cardoso RF.

Future Microbiol. 2019 Mar;14:331-344. doi: 10.2217/fmb-2018-0333. Epub 2019 Feb 13.

PMID:
30757916
4.

Anti-Mycobacterium tuberculosis activity of essential oil and 6,7-dehydroroyleanone isolated from leaves of Tetradenia riparia (Hochst.) Codd (Lamiaceae).

Baldin VP, Scodro RBL, Lopes-Ortiz MA, de Almeida AL, Gazim ZC, Ferarrese L, Faiões VDS, Torres-Santos EC, Pires CTA, Caleffi-Ferracioli KR, Siqueira VLD, Cortez DAG, Cardoso RF.

Phytomedicine. 2018 Aug 1;47:34-39. doi: 10.1016/j.phymed.2018.04.043. Epub 2018 Apr 24.

5.

Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.

Santos NCS, Scodro RBL, de Almeida AL, Baldin VP, Nakamura de Vasconcelos SS, Siqueira VLD, Caleffi-Ferracioli KR, Campanerut-Sá PAZ, Cardoso RF.

Tuberculosis (Edinb). 2018 Jul;111:41-44. doi: 10.1016/j.tube.2018.05.005. Epub 2018 May 19.

PMID:
30029913
6.

In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis.

Hegeto LA, Caleffi-Ferracioli KR, Nakamura-Vasconcelos SS, Almeida AL, Baldin VP, Nakamura CV, Siqueira VLD, Scodro RBL, Cardoso RF.

Tuberculosis (Edinb). 2018 Jul;111:35-40. doi: 10.1016/j.tube.2018.05.006. Epub 2018 May 14.

PMID:
30029912
7.

PIP30/FAM192A is a novel regulator of the nuclear proteasome activator PA28γ.

Jonik-Nowak B, Menneteau T, Fesquet D, Baldin V, Bonne-Andrea C, Méchali F, Fabre B, Boisguerin P, de Rossi S, Henriquet C, Pugnière M, Ducoux-Petit M, Burlet-Schiltz O, Lamond AI, Fort P, Boulon S, Bousquet MP, Coux O.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6477-E6486. doi: 10.1073/pnas.1722299115. Epub 2018 Jun 22.

8.

Carvacrol activity & morphological changes in Mycobacterium tuberculosis.

Nakamura de Vasconcelos SS, Caleffi-Ferracioli KR, Hegeto LA, Baldin VP, Nakamura CV, Stefanello TF, Freitas Gauze G, Yamazaki DA, Scodro RB, Siqueira VL, Cardoso RF.

Future Microbiol. 2018 Jun 1;13:877-888. doi: 10.2217/fmb-2017-0232. Epub 2018 Jun 7.

PMID:
29877104
9.

Synthesis of novel (-)-Camphene-based thiosemicarbazones and evaluation of anti-Mycobacterium tuberculosis activity.

Souza MRP, Coelho NP, Baldin VP, Scodro RBL, Cardoso RF, da Silva CC, Vandresen F.

Nat Prod Res. 2018 May 24:1-6. doi: 10.1080/14786419.2018.1478829. [Epub ahead of print]

PMID:
29792346
10.

RDRioMycobacterium tuberculosis lineage in the Brazil/Paraguay/Argentina triple border.

de Almeida AL, Scodro RBL, de Carvalho HC, Costacurta GF, Baldin VP, Santos NCS, Ghiraldi-Lopes LD, Campanerut-Sá PAZ, Siqueira VLD, Caleffi-Ferracioli KR, Shibata FK, Sprada A, Cardoso RF.

Tuberculosis (Edinb). 2018 May;110:68-78. doi: 10.1016/j.tube.2018.03.008. Epub 2018 Mar 31.

PMID:
29779776
11.

New insights on Ethambutol Targets in Mycobacterium tuberculosis.

Ghiraldi-Lopes LD, Campanerut-Sá PAZ, Evaristo GPC, Meneguello JE, Fiorini A, Baldin VP, de Souza EM, de Lima Scodro RB, Siqueira VLD, Cardoso RF.

Infect Disord Drug Targets. 2019;19(1):73-80. doi: 10.2174/1871526518666180124140840.

PMID:
29366429
12.

The stability of Fbw7α in M-phase requires its phosphorylation by PKC.

Zitouni S, Méchali F, Papin C, Choquet A, Roche D, Baldin V, Coux O, Bonne-Andrea C.

PLoS One. 2017 Aug 29;12(8):e0183500. doi: 10.1371/journal.pone.0183500. eCollection 2017.

13.

Evaluation of Chemical Composition and Antileishmanial and Antituberculosis Activities of Essential Oils of Piper Species.

Bernuci KZ, Iwanaga CC, Fernandez-Andrade CM, Lorenzetti FB, Torres-Santos EC, Faiões VD, Gonçalves JE, do Amaral W, Deschamps C, Scodro RB, Cardoso RF, Baldin VP, Cortez DA.

Molecules. 2016 Dec 12;21(12). pii: E1698. doi: 10.3390/molecules21121698.

14.

Evaluation of Chemical Composition and Antileishmanial and Antituberculosis Activities of Essential Oils of Piper Species.

Bernuci KZ, Iwanaga CC, Fernadez-Andrade CM, Lorenzetti FB, Torres-Santos EC, Faiões VD, Gonçalves JE, do Amaral W, Deschamps C, Scodro RB, Cardoso RF, Baldin VP, Cortez DA.

Molecules. 2016 Dec 12;21(12). pii: E1698.

15.

Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.

Pagliotto AD, Caleffi-Ferracioli KR, Lopes MA, Baldin VP, Leite CQ, Pavan FR, Scodro RB, Siqueira VL, Cardoso RF.

J Microbiol Immunol Infect. 2016 Dec;49(6):980-983. doi: 10.1016/j.jmii.2015.08.025. Epub 2015 Sep 21.

16.

Kizuna is a novel mitotic substrate for CDC25B phosphatase.

Thomas Y, Peter M, Mechali F, Blanchard JM, Coux O, Baldin V.

Cell Cycle. 2014;13(24):3867-77. doi: 10.4161/15384101.2014.972882.

17.

[Remote results of semiclosed endarterectomy with a loop from the superficial femoral artery and femoropopliteal bypass grafting].

Abramov IS, Maĭtesian DA, Lazarian TA, Baldin VL, Verigo AV, Eremenko AG, Papoian SA.

Angiol Sosud Khir. 2014;20(4):147-51. Russian.

PMID:
25490369
18.

First baseline of circulating genotypic lineages of Mycobacterium tuberculosis in patients from the brazilian borders with Argentina and Paraguay.

Machado LN, Marcondes NR, Leite CQ, Santos AC, Pavan FR, Baldin VP, Castilho AL, Siqueira VL, Baeza LC, Berghs H, Cardoso RF.

PLoS One. 2014 Sep 9;9(9):e107106. doi: 10.1371/journal.pone.0107106. eCollection 2014.

19.

High-resolution live-cell imaging reveals novel cyclin A2 degradation foci involving autophagy.

Loukil A, Zonca M, Rebouissou C, Baldin V, Coux O, Biard-Piechaczyk M, Blanchard JM, Peter M.

J Cell Sci. 2014 May 15;127(Pt 10):2145-50. doi: 10.1242/jcs.139188. Epub 2014 Mar 14.

20.

[Hybrid operations in multilevel lesions of lower-limb arteries].

Papoian SA, Abramov IS, Maĭtesian DA, Verigo AV, Eremenko AG, Baldin VL, Kirsanov IuK.

Angiol Sosud Khir. 2012;18(2):138-41. Russian.

PMID:
22929684
21.
22.

High yield bacterial expression and purification of active recombinant PA28alphabeta complex.

Le Feuvre AY, Dantas-Barbosa C, Baldin V, Coux O.

Protein Expr Purif. 2009 Apr;64(2):219-24. doi: 10.1016/j.pep.2008.10.014. Epub 2008 Nov 5.

23.

JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.

Farràs R, Baldin V, Gallach S, Acquaviva C, Bossis G, Jariel-Encontre I, Piechaczyk M.

Mol Cell Biol. 2008 Jun;28(12):4173-87. doi: 10.1128/MCB.01620-07. Epub 2008 Apr 7.

24.

A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking.

Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, Jariel-Encontre I, Piechaczyk M, Bertrand E, Tazi J, Coux O.

Mol Biol Cell. 2008 Apr;19(4):1706-16. doi: 10.1091/mbc.E07-07-0637. Epub 2008 Feb 6.

25.

[Death-tag].

Baldin V, Coux O.

Med Sci (Paris). 2004 Dec;20(12):1156-7. French. No abstract available.

26.

A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

Brezak MC, Quaranta M, Mondésert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.

Cancer Res. 2004 May 1;64(9):3320-5.

27.

PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation.

Baldin V, Theis-Febvre N, Benne C, Froment C, Cazales M, Burlet-Schiltz O, Ducommun B.

Biol Cell. 2003 Nov;95(8):547-54.

PMID:
14630392
28.

LIM-only protein FHL3 interacts with CDC25B2 phosphatase.

Mils V, Lee SM, Joly W, Hang EW, Baldin V, Waye MM, Ducommun B, Tsui SK.

Exp Cell Res. 2003 Apr 15;285(1):99-106.

PMID:
12681290
29.

Protein kinase CK2 regulates CDC25B phosphatase activity.

Theis-Febvre N, Filhol O, Froment C, Cazales M, Cochet C, Monsarrat B, Ducommun B, Baldin V.

Oncogene. 2003 Jan 16;22(2):220-32.

PMID:
12527891
30.

Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation.

Davezac N, Baldin V, Blot J, Ducommun B, Tassan JP.

Oncogene. 2002 Oct 31;21(50):7630-41.

31.

Nuclear localization of CDC25B1 and serine 146 integrity are required for induction of mitosis.

Baldin V, Pelpel K, Cazales M, Cans C, Ducommun B.

J Biol Chem. 2002 Sep 20;277(38):35176-82. Epub 2002 Jul 9.

32.

Study of the cytolethal distending toxin (CDT)-activated cell cycle checkpoint. Involvement of the CHK2 kinase.

Alby F, Mazars R, de Rycke J, Guillou E, Baldin V, Darbon JM, Ducommun B.

FEBS Lett. 2001 Mar 2;491(3):261-5.

33.

[Role of CDC25 phosphatases in the control of proliferation].

Davezac N, Ducommun B, Baldin V.

Pathol Biol (Paris). 2000 Apr;48(3):182-9. Review. French.

PMID:
10858952
34.

Study of the cytolethal distending toxin-induced cell cycle arrest in HeLa cells: involvement of the CDC25 phosphatase.

Escalas N, Davezac N, De Rycke J, Baldin V, Mazars R, Ducommun B.

Exp Cell Res. 2000 May 25;257(1):206-12.

PMID:
10854069
35.

Regulation of CDC25B phosphatases subcellular localization.

Davezac N, Baldin V, Gabrielli B, Forrest A, Theis-Febvre N, Yashida M, Ducommun B.

Oncogene. 2000 Apr 27;19(18):2179-85.

36.

14-3-3 proteins and growth control.

Baldin V.

Prog Cell Cycle Res. 2000;4:49-60. Review.

PMID:
10740814
37.

Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase.

Mils V, Baldin V, Goubin F, Pinta I, Papin C, Waye M, Eychene A, Ducommun B.

Oncogene. 2000 Mar 2;19(10):1257-65.

38.

Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage.

Chadebech P, Brichese L, Baldin V, Vidal S, Valette A.

Biochem Biophys Res Commun. 1999 Sep 7;262(3):823-7.

PMID:
10471409
39.

Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity.

Cans C, Sert V, De Rycke J, Baldin V, Ducommun B.

Anticancer Res. 1999 Mar-Apr;19(2A):1241-4.

PMID:
10368682
40.

Proteasome-dependent degradation of human CDC25B phosphatase.

Cans C, Ducommun B, Baldin V.

Mol Biol Rep. 1999 Apr;26(1-2):53-7. Review.

PMID:
10363647
41.

Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA.

Barboule N, Baldin V, JOzan S, Vidal S, Valette A.

Int J Cancer. 1998 Jun 10;76(6):891-6.

42.

Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation.

Baldin V, Cans C, Knibiehler M, Ducommun B.

J Biol Chem. 1997 Dec 26;272(52):32731-4.

43.

Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line.

Barboule N, Chadebech P, Baldin V, Vidal S, Valette A.

Oncogene. 1997 Dec 4;15(23):2867-75.

44.

Evidence for a mammalian Nim1-like kinase pathway acting at the G0-1/S transition.

Baldin V, Cans C, Watanabe N, Ducommun B.

Biochem Biophys Res Commun. 1997 Jul 9;236(1):130-4.

PMID:
9223439
45.

Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?

Baldin V, Cans C, Superti-Furga G, Ducommun B.

Oncogene. 1997 May 22;14(20):2485-95.

46.

Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts.

L'Allemain G, Lavoie JN, Rivard N, Baldin V, Pouyssegur J.

Oncogene. 1997 Apr 24;14(16):1981-90.

47.

Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma.

Barboule N, Mazars P, Baldin V, Vidal S, Jozan S, Martel P, Valette A.

Int J Cancer. 1995 Nov 27;63(5):611-5.

PMID:
7591274
48.

Subcellular localisation of human wee1 kinase is regulated during the cell cycle.

Baldin V, Ducommun B.

J Cell Sci. 1995 Jun;108 ( Pt 6):2425-32.

49.

Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells.

Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A.

FEBS Lett. 1995 Apr 10;362(3):295-300.

50.

PML nuclear bodies are general targets for inflammation and cell proliferation.

Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Hénin D, Dejean A.

Cancer Res. 1995 Apr 1;55(7):1590-7.

Supplemental Content

Loading ...
Support Center